Cogent Biosciences Announces Upcoming Presentations at AACR Annual Meeting 2022
March 08, 2022 17:10 ET
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences to Present at 11th Annual SVB Leerink Global Healthcare Conference
February 09, 2022 07:00 ET
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Unum Therapeutics Reports First Quarter Financial Results and Provides Corporate Updates
May 11, 2020 16:30 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced...
Unum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Updates
March 26, 2020 07:30 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., March 26, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today...
Unum Therapeutics Announces Common Stock Purchase Agreement for up to $25 Million with Lincoln Park Capital
March 20, 2020 07:30 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., March 20, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today...
Unum Therapeutics Implements Strategic Restructuring to Prioritize Efforts on BOXR1030 for the Treatment of Solid Tumor Cancers
March 02, 2020 08:45 ET
|
Unum Therapeutics Inc.
BOXR1030 is a GPC3-targeted CAR T cell incorporating the novel GOT2 transgene designed to improve T cell function in the solid tumor microenvironment by enhancing T cell metabolism Investigational...
Unum Therapeutics Provides Updates to its Phase 1 Trial of ACTR707 for HER2+ Solid Tumor Cancers
January 29, 2020 07:05 ET
|
Unum Therapeutics Inc.
-Cohort 1 enrollment is complete with no dose-limiting toxicities observed- -Cohort 2 patient screening underway- -Safety and efficacy data from multiple dose cohorts expected during 2020- ...
Unum Therapeutics Announces New Data at the American Society of Hematology (ASH) Annual Meeting
December 07, 2019 14:45 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Dec. 07, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today...
Unum Therapeutics to Present at Upcoming Investor Conference
November 15, 2019 07:30 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today...
Unum Therapeutics Reports Third Quarter 2019 Financial Results
November 12, 2019 16:30 ET
|
Unum Therapeutics Inc.
- Progress towards focusing on solid tumors remains on track with enrollment and early safety updates from Phase 1 trial of ACTR707 in HER2+ cancers expected by the end of this year- CAMBRIDGE,...